The FDA recently approved Vosevi-a fixed-dose combination tablet containing FDA-approved sofosbuvir and velpatasvir, and a new drug, voxilaprevi-to treat adults with the hepatitis C virus who do not have cirrhosis (liver disease).
The FDA recently approved Vosevi—a fixed-dose combination tablet containing FDA-approved sofosbuvir and velpatasvir, and a new drug, voxilaprevi—to treat adults with the hepatitis C virus (HCV) who do not have cirrhosis (liver disease).
Vosevi will be the first approved treatment for patients who have been treated with the direct-acting antiviral drug sofosbuvir or any other treatment that targets the NS5A protein.
“Direct-acting antiviral drugs prevent the virus from multiplying and often cure HCV,” Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past.”
The FDA approval includes the treatment of hepatitis C genotypes 1-6 that are genetically distinct versions of the virus. Approximately, 75% of Americans with HCV have genotype 1; 20% to 25% have genotypes 2 or 3; and the small number of remaining patients have genotypes 4, 5, or 6. By identifying the genotype, more specific treatment recommendations of Vosevi can be made.
Approximately 750 adults with the HCV participated in two Phase 3 clinical trials in order to test the safety and effectiveness of Vosevi. The first trial, over the course of 12 weeks, compared genotype 1 patients, who received a placebo and had previously received an unsuccessful NS5A inhibitor, with patients with genotype 2, 3, 4, 5 or 6 who all received Vosevi. The second trial included a comparison of Vosevi and the previously approved drugs sofosbuvir and velpatasvir in patients with genotypes 1, 2, or 3 who had an unsuccessful treatment with sofosbuvir.
The trial revealed 96% to 97% of patients who received Vosevi had no detection of the virus at 12 weeks following the treatment—demonstrating a potential cure.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More